NCT04346446View on ClinicalTrials.gov

Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

May 30, 2020

Study Completion Date

May 30, 2020

Conditions
COVID
Interventions
DRUG

Convalescent Plasma Transfusion

Convalescent Plasma Transfusion

OTHER

Supportive Care

Supportive Care

DRUG

Random Donor Plasma

Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement

Trial Locations (2)

110002

Maulana Azad medical College, New Delhi

110070

Institute of Liver and Biliary Sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT04346446 - Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients | Biotech Hunter | Biotech Hunter